X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ubrogepant-tablets-56703.pdf
https://news.abbvie.com/news/press-releases/results-published-in-lancet-show-ubrelvy-ubrogepant-reduces-headache-phase-migraine-attack-when-dosed-during-prodrome-migraine.htm
https://www.prnewswire.com/news-releases/abbvie-announces-serena-williams-as-spokesperson-to-shed-light-on-ubrelvy-ubrogepant-as-an-effective-treatment-option-for-migraine-attacks-301106556.html
https://www.fiercepharma.com/pharma/lilly-set-for-first-2020-launch-after-dea-scheduling-for-migraine-drug-reyvow
https://endpts.com/biohaven-celebrates-phii-iii-win-for-intranasal-cgrp-migraine-drug-amid-oral-race-with-allergan/
http://www.pharmafile.com/news/533938/allergans-acute-migraine-therapy-ubrogepant-shows-strength-phase-3
https://icer-review.org/announcements/icer-releases-draft-evidence-report-on-acute-migraine-therapies/
https://www.fiercepharma.com/marketing/biohaven-touts-oral-cgrp-data-moves-closer-to-regulatory-finish-line-and-maybe-m-a
https://www.prnewswire.com/news-releases/allergan-announces-fda-acceptance-of-new-drug-application-for-ubrogepant-for-the-acute-treatment-of-migraine-300809651.html
https://endpts.com/eyeing-blockbuster-migraine-market-allergan-unloads-second-set-of-positive-phiii-results-for-ubrogepant/
https://www.prnewswire.com/news-releases/allergan-announces-second-positive-phase-3-clinical-trial-for-ubrogepant----an-oral-cgrp-receptor-antagonist-for-the-acute-treatment-of-migraine-300637807.html
Market Place
Share 
